Metabolic Changes as a Diagnostic Indicator for Cancer

NCT ID: NCT02362776

Last Updated: 2015-02-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

426 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-10-31

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to determine whether metabolic changes occur in blood plasma of cancer patients, and whether these changes can be used as a biomarker to detect cancer. These analyses will be done by means of nuclear magnetic resonance (NMR) spectroscopy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

breast cancer patients

Venous blood sample

Intervention Type OTHER

Collection of a venous blood sample to investigate metabolic changes in blood

lung cancer patients

Venous blood sample

Intervention Type OTHER

Collection of a venous blood sample to investigate metabolic changes in blood

control subjects

Venous blood sample

Intervention Type OTHER

Collection of a venous blood sample to investigate metabolic changes in blood

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Venous blood sample

Collection of a venous blood sample to investigate metabolic changes in blood

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of breast or lung cancer (new lesion)

Exclusion Criteria

* Not fasted for at least 6 hours
* Plasma glucose concentration ≥ 200 mg/dl
* Intake of medication at the day of investigation
* History/treatment of cancer in the previous 5 years
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ziekenhuis Oost-Limburg

OTHER

Sponsor Role collaborator

Algemeen Ziekenhuis Vesalius

OTHER

Sponsor Role collaborator

Ziekenhuis Maas en Kempen

OTHER

Sponsor Role collaborator

Mariaziekenhuis Noord-Limburg

OTHER

Sponsor Role collaborator

Hasselt University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. dr. Michiel Thomeer

prof. dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michiel Thomeer, prof. dr.

Role: PRINCIPAL_INVESTIGATOR

Ziekenhuis Oost-Limburg

Kurt Baeten, dr.

Role: PRINCIPAL_INVESTIGATOR

Hasselt University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ziekenhuis Oost-Limburg

Genk, Limburg, Belgium

Site Status

Hasselt University

Hasselt, Limburg, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

References

Explore related publications, articles, or registry entries linked to this study.

Louis E, Adriaensens P, Guedens W, Vanhove K, Vandeurzen K, Darquennes K, Vansteenkiste J, Dooms C, de Jonge E, Thomeer M, Mesotten L. Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types? Ann Oncol. 2016 Jan;27(1):178-84. doi: 10.1093/annonc/mdv499. Epub 2015 Oct 20.

Reference Type DERIVED
PMID: 26487580 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

09/046U

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.